Open Access
- 29 November 2020
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 8 (12) , 551
Abstract
Adrenocortical carcinoma (ACC) represents one of the most aggressive endocrine tumors. In spite of a correct therapeutic strategy based on a multidisciplinary approach between endocrinologist, surgeon and oncologist, the prognosis is often poor. Surgery is the mainstay treatment in ACC. Mitotane, a dichloro-diphenyl-trichloro-ethane derivate, represents the main medical treatment of ACC in consideration of its adrenocytolitic activity and it is mainly employed as adjuvant treatment after complete surgical resection and for the treatment of advanced ACC. However, the use of mitotane as adjuvant therapy is still controversial, also in consideration of the retrospective nature of several studies. The recurrence of disease is frequent, especially in advanced disease at the diagnosis. Therefore, in these contexts, conventional chemotherapy must be considered in association with mitotane, being the combination etoposide, doxorubicin and cisplatin (EDP) the standard of care in this setting. A more modern therapeutic approach, based on the need of a salvage therapy for advanced ACC that progresses through first-line EDP, is focused on molecular-targeted therapies. However, robust clinical trials are necessary to assess the real efficacy of these treatments.Keywords
This publication has 112 references indexed in Scilit:
- DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical TumorsThe Journal of Clinical Endocrinology & Metabolism, 2012
- Association of adrenocortical carcinoma with familial cancer susceptibility syndromesMolecular and Cellular Endocrinology, 2012
- A Large Family with Carney Complex Caused by the S147G PRKAR1A Mutation Shows a Unique Spectrum of Disease Including Adrenocortical CancerThe Journal of Clinical Endocrinology & Metabolism, 2012
- Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumoursJournal of Clinical Pathology, 2011
- Li-Fraumeni SyndromeGenes & Cancer, 2011
- MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancyCancer, 2010
- Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical CarcinomaJournal of Clinical Oncology, 2009
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaCancer Chemotherapy and Pharmacology, 2009
- Prognostic Parameters of Metastatic Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2007
- Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor RegistryJournal of Clinical Oncology, 2004